Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 11/20 | 0.69 |
| ▸ | KDM5B | Q9UGL1 | 8/20 | 0.69 |
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.57 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.54 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17898957 | 0.93 | KDM2B (0.69) | KDM2BKDM5BKDM4CPHF8KDM4A | |
| SCHEMBL17693197 | 0.92 | KDM2B (0.58) | KDM2BKDM5BKDM4CPHF8 | |
| SCHEMBL17693187 | 0.92 | KDM2B (0.68) | KDM2BKDM5BKDM4CPHF8 | |
| SCHEMBL17898955 | 0.92 | KDM2B (0.68) | KDM2BKDM5BKDM4CPHF8 | |
| SCHEMBL17693200 | 0.92 | KDM2B (0.58) | KDM2BKDM5BKDM4CPHF8 | |
| SCHEMBL17693190 | 0.92 | KDM2B (0.68) | KDM2BKDM5BKDM4CPHF8 | |
| SCHEMBL17693212 | 0.91 | KDM2B (0.58) | KDM2BKDM5BKDM4CPHF8KDM4A | |
| SCHEMBL17693204 | 0.91 | KDM2B (0.58) | KDM2BKDM5BKDM4CPHF8KDM4A | |
| SCHEMBL17898917 | 0.90 | KDM5B (0.70) | KDM2BKDM5BKDM4CPHF8 | |
| SCHEMBL17693184 | 0.90 | KDM5B (0.70) | KDM2BKDM5BKDM4CPHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-9896436-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM2B 15/4885KDM5B 11/4885KDM4C 14/4885 |
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM2B 15/4885KDM5B 11/4885KDM4C 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.